SCHEMBL3351481

SCHEMBL3351481

CCCCCC(C(N)=O)C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.52
CA2 P00918 2/20 0.52
GPR84 Q9NQS5 6/20 0.46
FFAR1 O14842 1/20 0.46
EPHX1 P07099 1/20 0.45
LAP3 P28838 2/20 0.45
MAPT P10636 1/20 0.45
TP53 P04637 1/20 0.45
LCK P06239 1/20 0.45
PPARD Q03181 1/20 0.45
ZDHHC20 Q5W0Z9 1/20 0.45
ZDHHC2 Q9UIJ5 1/20 0.45
OPRM1 P35372 1/20 0.44
GRIK1 P39086 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
GRIK2 Q13002 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5983401 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL8600274 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL9000227 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL10499515 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL8626076 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL11725546 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL8603095 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL8601943 0.98 GPR84 (0.50) CA1CA2GPR84FFAR1EPHX1
SCHEMBL2494394 0.92 CA2 (0.60) CA1CA2GPR84FFAR1EPHX1
SCHEMBL27626820 0.91 GPR84 (0.54) CA1CA2GPR84FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108689874-A A kind of method and its application preparing 2- aryl malonamides 泸州东方农化有限公司 2018-10-23 CN disclosed
US-20170216335-A1 METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT PERICOR THERAPEUTICS INC (US) 2017-08-03 US disclosed
US-9539274-B2 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient PERICOR THERAPEUTICS, INC. (US) 2017-01-10 US disclosed
US-20150272978-A1 METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT PERICOR THERAPEUTICS, INC. 2015-10-01 US disclosed
CN-103131330-B Composition for polishing and use its Ginding process FUJIMI INC. (JP) 2015-09-23 CN disclosed
US-8993527-B2 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient PERICOR THERAPEUTICS, INC. (US) 2015-03-31 US disclosed
EP-2781522-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST Sumitomo Chemical Company, Limited (JP) 2014-09-24 EP disclosed
CN-103131330-A Polishing composition and polishing method using the same FUJIMI INC 2013-06-05 CN disclosed
EP-2594273-A1 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient Pericor Therapeutics, Inc. (US) 2013-05-22 EP disclosed
US-20120220753-A1 N-Terminal Dimerization Methods with Bis-Amindino Acid and Bis-Thioimidate Derivatives THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2012-08-30 US disclosed
EP-0495091-B1 AICA RIBOSIDE ANALOGS METABASIS THERAPEUTICS INC (US) 1999-11-24 EP disclosed
US-5777100-A INCREASING LEVELS OF ADENOSINE, CARDIOVASCULAR, ISCHEMIA GENSIA INC. (US) 1998-07-07 US disclosed
WO-1995033813-A1 IMPROVED DETERGENT COMPOSITION UNILEVER N.V. (NL) 1995-12-14 WO disclosed
EP-0542867-A4 METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS 1993-07-28 EP disclosed
EP-0542867-A1 METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS GENSIA, INC. (US) 1993-05-26 EP disclosed
EP-0495091-A4 AICA RIBOSIDE ANALOGS 1993-01-07 EP disclosed
EP-0495091-A1 AICA RIBOSIDE ANALOGS GENSIA, INC. (US) 1992-07-22 EP disclosed
WO-1992002214-A1 AICA RIBOSIDE ANALOGS GENSIA PHARMACEUTICALS, INC. (US) 1992-02-20 WO disclosed
WO-1992002213-A1 METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS GENSIA PHARMACEUTICALS, INC. (US) 1992-02-20 WO disclosed
US-4761355-A IODINE, BROMINE, OR IODINE BROMIDE AND POLYOXYETHYLENE GLYCOL MEDTRONIC, INC. (US) 1988-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272978-A1 METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT TNNC1, ASAH2, PGF CA1 205/4885CA2 324/4885GPR84 2567/4885
US-20120220753-A1 N-Terminal Dimerization Methods with Bis-Amindino Acid and Bis-Thioimidate Derivatives ERBB2, MAX, DNPEP CA1 2335/4885CA2 2964/4885GPR84 2852/4885
US-20170216335-A1 METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT TNNC1, ASAH2, PGF CA1 205/4885CA2 324/4885GPR84 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.